[2]
. Five-day nitrofurantoin is better than single-dose fosfomycin at resolving UTI symptoms. Drug and therapeutics bulletin. 2018 Nov:56(11):131. doi: 10.1136/dtb.2018.11.000039. Epub 2018 Oct 8
[PubMed PMID: 30297448]
[3]
Long B, Koyfman A. The Emergency Department Diagnosis and Management of Urinary Tract Infection. Emergency medicine clinics of North America. 2018 Nov:36(4):685-710. doi: 10.1016/j.emc.2018.06.003. Epub 2018 Sep 6
[PubMed PMID: 30296999]
[4]
Tang M, Quanstrom K, Jin C, Suskind AM. Recurrent Urinary Tract Infections are Associated With Frailty in Older Adults. Urology. 2019 Jan:123():24-27. doi: 10.1016/j.urology.2018.09.025. Epub 2018 Oct 6
[PubMed PMID: 30296501]
[6]
Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica. 2010 Apr:5(2):111-5
[PubMed PMID: 21977133]
Level 3 (low-level) evidence
[7]
Yamaji R, Friedman CR, Rubin J, Suh J, Thys E, McDermott P, Hung-Fan M, Riley LW. A Population-Based Surveillance Study of Shared Genotypes of Escherichia coli Isolates from Retail Meat and Suspected Cases of Urinary Tract Infections. mSphere. 2018 Aug 15:3(4):. doi: 10.1128/mSphere.00179-18. Epub 2018 Aug 15
[PubMed PMID: 30111626]
Level 3 (low-level) evidence
[9]
Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. Recent patents on inflammation & allergy drug discovery. 2019:13(1):2-18. doi: 10.2174/1872213X13666181228154940. Epub
[PubMed PMID: 30592257]
[10]
May M, Schostak M, Lebentrau S, MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. International urogynecology journal. 2019 Feb:30(2):335-336. doi: 10.1007/s00192-018-3851-8. Epub 2018 Dec 18
[PubMed PMID: 30564871]
[12]
Sakamoto S, Miyazawa K, Yasui T, Iguchi T, Fujita M, Nishimatsu H, Masaki T, Hasegawa T, Hibi H, Arakawa T, Ando R, Kato Y, Ishito N, Yamaguchi S, Takazawa R, Tsujihata M, Taguchi M, Akakura K, Hata A, Ichikawa T. Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan. International journal of urology : official journal of the Japanese Urological Association. 2019 Jan:26(1):96-101. doi: 10.1111/iju.13817. Epub 2018 Oct 11
[PubMed PMID: 30308705]
Level 2 (mid-level) evidence
[13]
Alperin M, Burnett L, Lukacz E, Brubaker L. The mysteries of menopause and urogynecologic health: clinical and scientific gaps. Menopause (New York, N.Y.). 2019 Jan:26(1):103-111. doi: 10.1097/GME.0000000000001209. Epub
[PubMed PMID: 30300297]
[14]
Maharjan G, Khadka P, Siddhi Shilpakar G, Chapagain G, Dhungana GR. Catheter-Associated Urinary Tract Infection and Obstinate Biofilm Producers. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale. 2018:2018():7624857. doi: 10.1155/2018/7624857. Epub 2018 Aug 26
[PubMed PMID: 30224941]
[15]
Sobel JD. New aspects of pathogenesis of lower urinary tract infections. Urology. 1985 Nov:26(5 Suppl):11-6
[PubMed PMID: 3904135]
[16]
Ipe DS, Horton E, Ulett GC. The Basics of Bacteriuria: Strategies of Microbes for Persistence in Urine. Frontiers in cellular and infection microbiology. 2016:6():14. doi: 10.3389/fcimb.2016.00014. Epub 2016 Feb 8
[PubMed PMID: 26904513]
[18]
Kucheria R, Dasgupta P, Sacks SH, Khan MS, Sheerin NS. Urinary tract infections: new insights into a common problem. Postgraduate medical journal. 2005 Feb:81(952):83-6
[PubMed PMID: 15701738]
[19]
Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric oxide : biology and chemistry. 2001 Dec:5(6):580-6
[PubMed PMID: 11730365]
[20]
Cornish J, Lecamwasam JP, Harrison G, Vanderwee MA, Miller TE. Host defence mechanisms in the bladder. II. Disruption of the layer of mucus. British journal of experimental pathology. 1988 Dec:69(6):759-70
[PubMed PMID: 3064799]
[21]
Abraham SN, Miao Y. The nature of immune responses to urinary tract infections. Nature reviews. Immunology. 2015 Oct:15(10):655-63. doi: 10.1038/nri3887. Epub 2015 Sep 21
[PubMed PMID: 26388331]
[22]
Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science (New York, N.Y.). 1998 Nov 20:282(5393):1494-7
[PubMed PMID: 9822381]
[23]
Hudson PL, Hung KJ, Bergerat A, Mitchell C. Effect of Vaginal Lactobacillus Species on Escherichia coli Growth. Female pelvic medicine & reconstructive surgery. 2020 Feb:26(2):146-151. doi: 10.1097/SPV.0000000000000827. Epub
[PubMed PMID: 31990804]
[24]
Bunduki GK, Heinz E, Phiri VS, Noah P, Feasey N, Musaya J. Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a systematic review and meta-analysis. BMC infectious diseases. 2021 Aug 4:21(1):753. doi: 10.1186/s12879-021-06435-7. Epub 2021 Aug 4
[PubMed PMID: 34348646]
Level 1 (high-level) evidence
[25]
Paudel S, John PP, Poorbaghi SL, Randis TM, Kulkarni R. Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes. Journal of diabetes research. 2022:2022():3588297. doi: 10.1155/2022/3588297. Epub 2022 May 17
[PubMed PMID: 35620571]
Level 1 (high-level) evidence
[26]
Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. Journal of the American Geriatrics Society. 2009 Jun:57(6):963-70. doi: 10.1111/j.1532-5415.2009.02227.x. Epub
[PubMed PMID: 19490243]
[27]
Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Van Ness PH, Quagliarello V. Interobserver variability in the assessment of clinical criteria for suspected urinary tract infection in nursing home residents. Infection control and hospital epidemiology. 2008 May:29(5):446-9. doi: 10.1086/586721. Epub
[PubMed PMID: 18419369]
[28]
Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014 Feb 26:311(8):844-54. doi: 10.1001/jama.2014.303. Epub
[PubMed PMID: 24570248]
[30]
Richards KA, Cesario S, Best SL, Deeren SM, Bushman W, Safdar N. Reflex urine culture testing in an ambulatory urology clinic: Implications for antibiotic stewardship in urology. International journal of urology : official journal of the Japanese Urological Association. 2019 Jan:26(1):69-74. doi: 10.1111/iju.13803. Epub 2018 Sep 16
[PubMed PMID: 30221416]
[31]
Araujo da Silva AR, Marques AF, Biscaia di Biase C, Zingg W, Dramowski A, Sharland M. Interventions to prevent urinary catheter-associated infections in children and neonates: a systematic review. Journal of pediatric urology. 2018 Dec:14(6):556.e1-556.e9. doi: 10.1016/j.jpurol.2018.07.011. Epub 2018 Jul 21
[PubMed PMID: 30126746]
Level 1 (high-level) evidence
[33]
Suresh J, Krishnamurthy S, Mandal J, Mondal N, Sivamurukan P. Diagnostic Accuracy of Point-of-care Nitrite and Leukocyte Esterase Dipstick Test for the Screening of Pediatric Urinary Tract Infections. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2021 May-Jun:32(3):703-710. doi: 10.4103/1319-2442.336765. Epub
[PubMed PMID: 35102912]
[34]
Chernaya A, Søborg C, Midttun M. Validity of the urinary dipstick test in the diagnosis of urinary tract infections in adults. Danish medical journal. 2021 Dec 15:69(1):. pii: A07210607. Epub 2021 Dec 15
[PubMed PMID: 34913433]
[35]
Malia L, Strumph K, Smith S, Brancato J, Johnson ST, Chicaiza H. Fast and Sensitive: Automated Point-of-Care Urine Dips. Pediatric emergency care. 2020 Oct:36(10):486-488. doi: 10.1097/PEC.0000000000001357. Epub
[PubMed PMID: 29189595]
[36]
Bellazreg F, Abid M, Lasfar NB, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study. The Pan African medical journal. 2019:33():131. doi: 10.11604/pamj.2019.33.131.17190. Epub 2019 Jun 21
[PubMed PMID: 31558930]
Level 2 (mid-level) evidence
[37]
Little P, Turner S, Rumsby K, Warner G, Moore M, Lowes JA, Smith H, Hawke C, Turner D, Leydon GM, Arscott A, Mullee M. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health technology assessment (Winchester, England). 2009 Mar:13(19):iii-iv, ix-xi, 1-73. doi: 10.3310/hta13190. Epub
[PubMed PMID: 19364448]
Level 1 (high-level) evidence
[38]
Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 Apr 15:38(8):1150-8
[PubMed PMID: 15095222]
[39]
Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. The Journal of urology. 2019 Aug:202(2):282-289. doi: 10.1097/JU.0000000000000296. Epub 2019 Jul 8
[PubMed PMID: 31042112]
[40]
Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infectious disease clinics of North America. 2003 Jun:17(2):243-59
[PubMed PMID: 12848469]
[41]
Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, Lavi I, Stamm W, Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002 May 1:34(9):1165-9
[PubMed PMID: 11941541]
[42]
Stein GE. Single-dose treatment of acute cystitis with fosfomycin tromethamine. The Annals of pharmacotherapy. 1998 Feb:32(2):215-9
[PubMed PMID: 9496408]
[43]
Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. International journal of antimicrobial agents. 2022 May:59(5):106574. doi: 10.1016/j.ijantimicag.2022.106574. Epub 2022 Mar 18
[PubMed PMID: 35307561]
[44]
Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. [Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis]. Urologiia (Moscow, Russia : 1999). 2018 Dec:(6):70-75
[PubMed PMID: 30742381]
[45]
Jo JK, Kim DS, Sim Y, Ryu S, Kim KS. A Comparative Study of Urinary Tests and Cultures for the Effectiveness of Fosfomycin in Catheter-Related Urinary Tract Infections. Journal of clinical medicine. 2022 Dec 5:11(23):. doi: 10.3390/jcm11237229. Epub 2022 Dec 5
[PubMed PMID: 36498803]
Level 2 (mid-level) evidence
[46]
O'Grady MC, Barry L, Corcoran GD, Hooton C, Sleator RD, Lucey B. Empirical treatment of urinary tract infections: how rational are our guidelines? The Journal of antimicrobial chemotherapy. 2019 Jan 1:74(1):214-217. doi: 10.1093/jac/dky405. Epub
[PubMed PMID: 30295780]
[47]
Ditkoff EL, Theofanides M, Aisen CM, Kowalik CG, Cohn JA, Sui W, Rutman M, Adam RA, Dmochowski RR, Cooper KL. Assessment of practices in screening and treating women with bacteriuria. The Canadian journal of urology. 2018 Oct:25(5):9486-9496
[PubMed PMID: 30281006]
[48]
Ganzeboom KMJ, Uijen AA, Teunissen DTAM, Assendelft WJJ, Peters HJG, Hautvast JLA, Van Jaarsveld CHM. Urine cultures and antibiotics for urinary tract infections in Dutch general practice. Primary health care research & development. 2018 Aug 31:20():e41. doi: 10.1017/S146342361800066X. Epub 2018 Aug 31
[PubMed PMID: 30168406]
[49]
Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. International journal of antimicrobial agents. 2003 Oct:22 Suppl 2():73-8
[PubMed PMID: 14527775]
[50]
Stair SL, Palmer CJ, Lee UJ. Evidence-based review of nonantibiotic urinary tract infection prevention strategies for women: a patient-centered approach. Current opinion in urology. 2023 May 1:33(3):187-192. doi: 10.1097/MOU.0000000000001082. Epub 2023 Mar 2
[PubMed PMID: 36862100]
Level 3 (low-level) evidence
[51]
Konesan J, Liu L, Mansfield KJ. The Clinical Trial Outcomes of Cranberry, D-Mannose and NSAIDs in the Prevention or Management of Uncomplicated Urinary Tract Infections in Women: A Systematic Review. Pathogens (Basel, Switzerland). 2022 Dec 5:11(12):. doi: 10.3390/pathogens11121471. Epub 2022 Dec 5
[PubMed PMID: 36558804]
Level 1 (high-level) evidence
[52]
Bakhit M, Krzyzaniak N, Hilder J, Clark J, Scott AM, Mar CD. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. The British journal of general practice : the journal of the Royal College of General Practitioners. 2021 Jul:71(708):e528-e537. doi: 10.3399/BJGP.2020.0833. Epub 2021 Jun 24
[PubMed PMID: 34001538]
Level 1 (high-level) evidence
[53]
Botros C, Lozo S, Iyer S, Warren A, Goldberg R, Tomezsko J, Sasso K, Sand P, Gafni-Kane A, Biener A, Botros-Brey S. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. International urogynecology journal. 2022 Mar:33(3):571-580. doi: 10.1007/s00192-021-04849-0. Epub 2021 Jun 11
[PubMed PMID: 34115162]
Level 1 (high-level) evidence
[54]
Bartlett JE, De Bellis A. The prevention of urinary tract infections in aged care residents through the use of cranberry products: a critical analysis of the literature. Contemporary nurse. 2022 Aug:58(4):296-316. doi: 10.1080/10376178.2022.2104332. Epub 2022 Aug 6
[PubMed PMID: 35861109]
[55]
Jeitler M, Michalsen A, Schwiertz A, Kessler CS, Koppold-Liebscher D, Grasme J, Kandil FI, Steckhan N. Effects of a Supplement Containing a Cranberry Extract on Recurrent Urinary Tract Infections and Intestinal Microbiota: A Prospective, Uncontrolled Exploratory Study. Journal of integrative and complementary medicine. 2022 May:28(5):399-406. doi: 10.1089/jicm.2021.0300. Epub 2022 Mar 14
[PubMed PMID: 35285701]
[56]
Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. Effectiveness of a Combination of Cranberries, Lactobacillus rhamnosus, and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study. European urology. 2016 Dec:70(6):912-915. doi: 10.1016/j.eururo.2016.05.042. Epub 2016 Jun 7
[PubMed PMID: 27283213]
Level 3 (low-level) evidence
[57]
Barea BM, Veeratterapillay R, Harding C. Nonantibiotic treatments for urinary cystitis: an update. Current opinion in urology. 2020 Nov:30(6):845-852. doi: 10.1097/MOU.0000000000000821. Epub
[PubMed PMID: 33009152]
Level 3 (low-level) evidence
[58]
Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World journal of urology. 2014 Feb:32(1):79-84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30
[PubMed PMID: 23633128]
Level 1 (high-level) evidence
[59]
Faustino M, Silva S, Costa EM, Pereira AM, Pereira JO, Oliveira AS, Ferreira CMH, Pereira CF, Durão J, Pintado ME, Carvalho AP. Effect of Mannan Oligosaccharides Extracts in Uropathogenic Escherichia coli Adhesion in Human Bladder Cells. Pathogens (Basel, Switzerland). 2023 Jun 28:12(7):. doi: 10.3390/pathogens12070885. Epub 2023 Jun 28
[PubMed PMID: 37513732]
[60]
Salvatore S, Ruffolo AF, Stabile G, Casiraghi A, Zito G, De Seta F. A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections. European urology focus. 2023 Jul:9(4):654-659. doi: 10.1016/j.euf.2022.12.013. Epub 2023 Jan 6
[PubMed PMID: 36621376]
Level 1 (high-level) evidence
[61]
Wagenlehner F, Lorenz H, Ewald O, Gerke P. Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infections-Preliminary Considerations and Conclusions from a Non-Interventional Study. Antibiotics (Basel, Switzerland). 2022 Feb 25:11(3):. doi: 10.3390/antibiotics11030314. Epub 2022 Feb 25
[PubMed PMID: 35326777]
[62]
Parazzini F, Ricci E, Fedele F, Chiaffarino F, Esposito G, Cipriani S. Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review). Biomedical reports. 2022 Aug:17(2):69. doi: 10.3892/br.2022.1552. Epub 2022 Jun 15
[PubMed PMID: 35815191]
Level 1 (high-level) evidence
[63]
Lenger SM, Chu CM, Ghetti C, Durkin MJ, Jennings Z, Wan F, Sutcliffe S, Lowder JL. d-Mannose for Recurrent Urinary Tract Infection Prevention in Postmenopausal Women Using Vaginal Estrogen: A Randomized Controlled Trial. Urogynecology (Philadelphia, Pa.). 2023 Mar 1:29(3):367-377. doi: 10.1097/SPV.0000000000001270. Epub 2022 Oct 15
[PubMed PMID: 36808931]
Level 1 (high-level) evidence
[64]
Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial. Female pelvic medicine & reconstructive surgery. 2021 Feb 1:27(2):112-117. doi: 10.1097/SPV.0000000000000749. Epub
[PubMed PMID: 31232721]
Level 1 (high-level) evidence
[65]
Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA internal medicine. 2018 Nov 1:178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204. Epub
[PubMed PMID: 30285042]
Level 1 (high-level) evidence
[66]
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. The Cochrane database of systematic reviews. 2004:2004(3):CD001209
[PubMed PMID: 15266443]
Level 1 (high-level) evidence
[67]
Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations. The Journal of urology. 2018 Dec:200(6):1174-1191. doi: 10.1016/j.juro.2018.04.088. Epub 2018 Jun 22
[PubMed PMID: 29940246]
[68]
Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. The Journal of infectious diseases. 1988 Jun:157(6):1239-42
[PubMed PMID: 3259613]
[69]
Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infectious disease clinics of North America. 1987 Dec:1(4):793-806
[PubMed PMID: 3333659]
[70]
Liu Y, Xiao D, Shi XH. Urinary tract infection control in intensive care patients. Medicine. 2018 Sep:97(38):e12195. doi: 10.1097/MD.0000000000012195. Epub
[PubMed PMID: 30235665]
[71]
Li F, Song M, Xu L, Deng B, Zhu S, Li X. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. Journal of advanced nursing. 2019 Mar:75(3):517-527. doi: 10.1111/jan.13863. Epub 2018 Dec 21
[PubMed PMID: 30259542]
Level 1 (high-level) evidence
[72]
Lengetti E, Kronk R, Ulmer KW, Wilf K, Murphy D, Rosanelli M, Taylor A. An innovative approach to educating nurses to clinical competence: A randomized controlled trial. Nurse education in practice. 2018 Nov:33():159-163. doi: 10.1016/j.nepr.2018.08.007. Epub 2018 Sep 8
[PubMed PMID: 30253916]
Level 1 (high-level) evidence
[73]
Vachhani AV, Barvaliya M, Naik V, Jha P, Tripathi C. Effectiveness and tolerability of short course co-trimoxazole, norfloxacin and levofloxacin in bacteriological cure of uncomplicated urinary tract infection in outpatient setting. An open label, parallel group, randomized controlled trial. Le infezioni in medicina. 2015 Jun:23(2):155-60
[PubMed PMID: 26110296]
Level 1 (high-level) evidence
[74]
Duane S, Beecher C, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D. A systematic review of the outcomes reported in the treatment of uncomplicated urinary tract infection clinical trials. JAC-antimicrobial resistance. 2022 Apr:4(2):dlac025. doi: 10.1093/jacamr/dlac025. Epub 2022 Mar 22
[PubMed PMID: 35350132]
Level 1 (high-level) evidence
[75]
Lodise TP, Henriksen AS, Hadley T, Patel N. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales. Open forum infectious diseases. 2021 Oct:8(10):ofab380. doi: 10.1093/ofid/ofab380. Epub 2021 Oct 15
[PubMed PMID: 34660834]
[76]
Fuchs F, Hamprecht A. Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales. Antimicrobial agents and chemotherapy. 2019 Apr:63(4):. doi: 10.1128/AAC.02402-18. Epub 2019 Mar 27
[PubMed PMID: 30917983]
[77]
Kahlmeter G, Åhman J, Matuschek E. Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008. Infectious diseases and therapy. 2015 Dec:4(4):417-23. doi: 10.1007/s40121-015-0095-5. Epub 2015 Oct 27
[PubMed PMID: 26507395]
[78]
Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. International journal of antimicrobial agents. 2012 Jan:39(1):45-51. doi: 10.1016/j.ijantimicag.2011.09.013. Epub 2011 Nov 3
[PubMed PMID: 22055529]
[79]
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Mar 1:52(5):e103-20. doi: 10.1093/cid/ciq257. Epub
[PubMed PMID: 21292654]
Level 1 (high-level) evidence
[81]
Jansåker F, Thønnings S, Hertz FB, Kallemose T, Værnet J, Bjerrum L, Benfield T, Frimodt-Møller N, Knudsen JD. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine. 2019 Jul:12():62-69. doi: 10.1016/j.eclinm.2019.06.009. Epub 2019 Jul 20
[PubMed PMID: 31388664]
Level 1 (high-level) evidence
[82]
Jodal U, Larsson P, Hansson S, Bauer CA. Pivmecillinam in long-term prophylaxis to girls with recurrent urinary tract infection. Scandinavian journal of infectious diseases. 1989:21(3):299-302
[PubMed PMID: 2756342]
[83]
Bollestad M, Grude N, Solhaug S, Raffelsberger N, Handal N, Nilsen HS, Romstad MR, Emmert A, Tveten Y, Søraas A, Jenum PA, Jenum S, Møller-Stray J, Weme ET, Lindbaek M, Simonsen GS, (the Norwegian ESBL UTI study group). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. The Journal of antimicrobial chemotherapy. 2018 Sep 1:73(9):2503-2509. doi: 10.1093/jac/dky230. Epub
[PubMed PMID: 29982514]
[84]
Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. The Journal of antimicrobial chemotherapy. 2014 Mar:69(3):769-72. doi: 10.1093/jac/dkt404. Epub 2013 Oct 9
[PubMed PMID: 24107388]